Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 16/20 | 0.46 |
| ▸ | CCKAR | P32238 | 13/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL541718 | 1.00 | CCKBR (0.46) | CCKBRCCKARALDH1A1POLB | |
| SCHEMBL1394355 | 1.00 | CCKBR (0.46) | CCKBRCCKARALDH1A1POLB | |
| SCHEMBL6193195 | 1.00 | CCKBR (0.46) | CCKBRCCKARALDH1A1POLB | |
| SCHEMBL6178926 | 1.00 | CCKBR (0.46) | CCKBRCCKARALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL6178190 | 0.99 | CCKBR (0.45) | CCKBRCCKARALDH1A1POLB | |
| SCHEMBL6180501 | 0.99 | CCKBR (0.44) | CCKBRCCKARALDH1A1POLB | |
| Oxalic Acid SCHEMBL6821965 | 0.97 | CCKBR (0.44) | CCKBRCCKARALDH1A1POLB | |
| Oxalic Acid SCHEMBL6821968 | 0.97 | CCKBR (0.44) | CCKBRCCKARALDH1A1POLB | |
| Oxalic Acid SCHEMBL6824565 | 0.96 | CCKBR (0.43) | CCKBRCCKARALDH1A1POLB | |
| Oxalic Acid SCHEMBL6824572 | 0.96 | CCKBR (0.43) | CCKBRCCKARALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10786580-B2 | Cholecystokinin 2 receptor targeted NIR imaging and use thereof | On Target Laboratories, LLC (US) | 2020-09-29 | — | — | US | disclosed |
| EP-3509617-A1 | CHOLECYSTOKININ 2 RECEPTOR TARGETED NIR IMAGING AND USE THEREOF | On Target Laboratories, LLC (US) | 2019-07-17 | — | — | EP | disclosed |
| WO-2018049129-A1 | CHOLECYSTOKININ 2 RECEPTOR TARGETED NIR IMAGING AND USE THEREOF | On Target Laboratories, LLC (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20180071408-A1 | CHOLECYSTOKININ 2 RECEPTOR TARGETED NIR IMAGING AND USE THEREOF | On Target Laboratories, Inc. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071408-A1 | CHOLECYSTOKININ 2 RECEPTOR TARGETED NIR IMAGING AND USE THEREOF | CCKAR, CCKBR, GRPR | CCKBR 2/4885CCKAR 1/4885ALDH1A1 4532/4885 |
| US-10786580-B2 | Cholecystokinin 2 receptor targeted NIR imaging and use thereof | CCKAR, CCKBR, GRPR | CCKBR 2/4885CCKAR 1/4885ALDH1A1 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.